Arrowhead price target lowered to $81 from $84 at BofA

BofA lowered the firm’s price target on Arrowhead (ARWR) to $81 from $84 and keeps a Buy rating on the shares. Arrowhead shares fell modestly on mixed competitor INHBE data, though the update appears largely priced in, the analyst tells investors in a research note. The core thesis remains centered on value unlock from the APOC3 sHTG opportunity ahead of the Phase 3 Shasta-3/4 readouts in 3Q26, with expectations that Arrowhead and Ionis Pharmaceuticals (IONS) will split the market and benefit from growing peak sales potential, the firm says.